By using CD105 (also known as endoglin, which is a validated marker for tumor angiogenesis and almost exclusively expressed on proliferating tumor endothelial cells14, 15) based tumor vasculature targeting strategy, we achieved over 3-fold higher tumor uptake (~10%ID/g at 4 h post-injection [p.i.]) in targeted group when compared with the non-targeted group (~3%ID/g at 4 h p.i.). Here, ENG is linked to neoplasm.